The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV.

This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research.

This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, prevent suicide attempts (nonfatal and fatal), and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and sett

The goal of amfAR’s Mathilde Krim Fellowships in Basic Biomedical Research is to: facilitate the exceptional postdoctoral researcher’s transition to an independent career in HIV/AIDS research within an academic institution or nonprofit organization; support two years of postdoctoral basic biomedical research (phase I); provide the possibility of one additional year of research funding during the first year of an independent research position (phase II).